...

CCO Independent Conference Coverage

CCO Independent Conference Coverage of the 2008 ICAAC/IDSA Annual Meeting*

October 25-28, 2008 | Washington, DC

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.

Timing and Choice of First-Line Antiretroviral Therapy

Track 1 of 6

Faculty:

Joel E. Gallant, MD, MPHW. David Hardy, MDKathleen E. Squires, MD
  • Joel E. Gallant, MD, MPH
  • W. David Hardy, MD
  • Kathleen E. Squires, MD

Management of Treatment-Experienced Patients

Track 2 of 6

Faculty:

Eric S. Daar, MDJoseph J. Eron, Jr., MDKimberly Y. Smith, MD, MPH
  • Eric S. Daar, MD
  • Joseph J. Eron, Jr., MD
  • Kimberly Y. Smith, MD, MPH

Clinical Complications of HIV and Its Therapy

Track 3 of 6

Faculty:

Judith S. Currier, MD, MScDonald P. Kotler, MDWilliam G. Powderly, MD
  • Judith S. Currier, MD, MSc
  • Donald P. Kotler, MD
  • William G. Powderly, MD

Hepatitis and Opportunistic Coinfections

Track 4 of 6

Faculty:

Richard E. Chaisson, MDSally Hodder, MDBruce Polsky, MD
  • Richard E. Chaisson, MD
  • Sally Hodder, MD
  • Bruce Polsky, MD

New Agents

Track 5 of 6

Overview of the 2008 ICAAC/IDSA Annual Meeting

Track 6 of 6

Expert Highlights

Antiretroviral Therapy in Treatment-Naive Patients

Now Playing...

Anton L. Pozniak, MD, FRCP, reports on the 96-week results from the CASTLE, ARTEMIS, and HEAT clinical trials in treatment-naive patients as well as several analyses on the use of abacavir in patients with high HIV-1 RNA

Downloadable Formats:

Audio File 7.85 MB


 

Mouse over thumbnails for more information on the segments
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.

Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.

Contact Info

Educational grants provided by:

Educational grants support only the CME-certified components of this program.

Capsule Summary:

HIV-1 RNA Suppression With Tenofovir/Emtricitabine vs Abacavir/Lamivudine in First-Line Boosted PI-Based HAART in Systematic Review of 12 Studies

Systematic review of 12 trials suggests higher rates of virologic suppression with tenofovir/emtricitabine vs abacavir/emtricitabine when combined with atazanavir/ritonavir, fosamprenavir/ritonavir, or lopinavir/ritonavir, but analysis unable to account for discontinuations due to suspected abacavir hypersensitivity in the era before the availability of HLAB*5701 screening

CLICK HERE TO KEEP READING

CLICK HERE FOR RELATED CAPSULE SUMMARIES